Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naropin for postsurgical pain after Cesarean delivery
NCT02959476Phase 3Completed
- Sponsor
- BioQ Pharma
- Start
- Mar 2017
- Primary completion
- Aug 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postoperative pain comparing Ropivacaine 0.2% with Placebo (2 arms). Primary endpoint: Cumulative analgesic effect at 48 hours. Started Mar 2017; status: completed.
02
Drugs
ropivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT02959476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02959476.